www.nature.com/mp

ORIGINAL ARTICLE The nucleus reuniens: a key node in the neurocircuitry of stress and depression

V Kafetzopoulos¹, N Kokras^{1,2}, I Sotiropoulos^{3,4}, JF Oliveira^{3,4}, H Leite-Almeida^{3,4}, A Vasalou¹, VM Sardinha^{3,4}, Z Papadopoulou-Daifoti^{1,*}, OFX Almeida⁵, K Antoniou⁶, N Sousa^{3,4} and C Dalla¹

The hippocampus and prefrontal cortex (PFC) are connected in a reciprocal manner: whereas the hippocampus projects directly to the PFC, a polysynaptic pathway that passes through the nucleus reuniens (RE) of the thalamus relays inputs from the PFC to the hippocampus. The present study demonstrates that lesioning and/or inactivation of the RE reduces coherence in the PFC–hippocampal pathway, provokes an antidepressant-like behavioral response in the forced swim test and prevents, but does not ameliorate, anhedonia in the chronic mild stress (CMS) model of depression. Additionally, RE lesioning before CMS abrogates the well-known neuromorphological and endocrine correlates of CMS. In summary, this work highlights the importance of the reciprocal connectivity between the hippocampus and PFC in the establishment of stress-induced brain pathology and suggests a role for the RE in promoting resilience to depressive illness.

Molecular Psychiatry advance online publication, 11 April 2017; doi:10.1038/mp.2017.55

INTRODUCTION

Disruption of the pathways linking the prefrontal cortex (PFC) and hippocampus is thought to underlie major depressive disorder.^{1–4} The PFC receives a monosynaptic innervation from the ventral CA1 and subiculum of the hippocampus and there is a directionality in this communication because hippocampal activity leads the activity in the PFC.^{5,6} In contrast, the reciprocal PFC output to the hippocampus is not monosynaptic but relayed via the nucleus reuniens (RE), a thalamic midline nucleus⁷ (Figures 1a and b). The RE influences PFC and hippocampal activity,^{8,9} presumably by modulating oscillatory patterns between these two brain structures.^{10,11}

Although RE-dependent coordinated PFC–hippocampal activity was recently linked to working and spatial memory, passive avoidance learning and fear responses,^{8,12–14} no information on the possible involvement of the RE on the appearance of and recovery from depressive-like symptoms is currently available.

We therefore investigated the possible involvement of the RE in depression using the chronic mild stress (CMS), a paradigm of depressive-like behavior in rodents, and the forced swim test (FST), a paradigm for testing potential antidepressant interventions. Moreover, we examined the impact of RE lesioning on the synchronized activity of the PFC and hippocampus, as well as on neuromorphological and endocrine correlates of depressive-like behavior. These preclinical studies suggest that the RE occupies a central position in the neurocircuitry that underpins depression.

MATERIALS AND METHODS

Animals

Adult male Wistar rats (3 months old, 300–350 g at the beginning of the experiment) were used. All animals were housed under controlled light/

dark cycle (12:12 h, lights on at 0800 hours) and constant temperature/ humidity (22 °C/30–40%). Animals had *ad libitum* access to food and water, unless dictated otherwise by specific test protocols; they were randomly selected and allocated to treatment/surgery groups, except as otherwise noted (see experiment 3). Animals were single-housed postsurgery. Behavioral tests were carried out in the light phase. All behavioral experiments and scoring, as well as neurobiological procedures were performed by raters blind to the group allocation. Procedures on animal experiments were reviewed and approved by the relevant local ethics committee and studies were carried out in accordance with European Union Directive 2010/63/EU on animal care and experimentation.

Surgical procedure for RE lesions. Animals were anesthetized by intraperitoneal (i.p.) injection of a mixture of ketamine and xylazine¹⁵ (100 and 10 mg kg⁻¹, respectively) and placed in a stereotaxic frame (David Kopf Instruments, Tujunga, CA, USA). The RE lesions were performed by injecting 0.6 µl of 100 mm *N*-methyl-*D*-aspartate (in 0.1 m phosphate-buffered saline (PBS), pH = 7.4; 0.1 µl min⁻¹) or vehicle (0.1 m PBS, pH = 7.4) directly into the RE (+2.3 mm AP, ± 1.7 mm ML, and - 6.2 mm DV from bregma);^{16,17} the syringe was left in place for an additional 5 min to ensure adequate diffusion.^{16,18-20} The RE was accessed at a mediolateral angle of 15° to avoid damage to midline brain structures and vessels, and injections were alternated between left and right angles of access to randomize possible lateralized brain damage.²¹ Animals were closely monitored after surgery, returned to their home cages and allowed to recover for 1 week before further testing.

Histological verification of RE targeting. Brain sections were lightly stained with cresyl violet or hematoxylin to verify correct placement of cannulae and the extent of RE lesions. Lesion size (area) was estimated according to the presence of characteristic signs of excitotoxic reaction (loss of neurons or tissue, proliferation of microglial cells, pyknotic nuclei and accumulation of hemosiderin).¹⁶ The area of the lesion, relative to the whole RE, was estimated using the Stereoinvestigator software (MicroBrightField, Williston, VT, USA), with reference to the Paxinos and Watson atlas;¹⁷ data are shown in Supplementary Figure S1. Animals with lesion ratios < 50% were

¹Department of Pharmacology, Medical School, National and Kapodistrian University of Athens, Athens, Greece; ²First Department of Psychiatry, Eginition Hospital, National and Kapodistrian University of Athens, Athens, Greece; ³Life and Health Sciences Research Institute (ICVS), University of Minho, Braga, Portugal; ⁴ICVS/3B's, PT Government Associate Laboratory, Braga, Portugal; ⁵NeuroAdaptations Group, Max Planck Institute of Psychiatry, Munich, Germany and ⁶Department of Pharmacology, University of Ioannina, Ioannina, Greece. Correspondence: Professor C Dalla, Department of Pharmacology, Medical School, National and Kapodistrian University of Athens, Mikras Asias 75, Athens 11527, Greece. E-mail: cdalla@med.uoa.gr

*Deceased.

Received 8 September 2014; revised 14 February 2017; accepted 16 February 2017

Role of the nucleus reuniens V Kafetzopoulos *et al*



Figure 1. Nucleus reuniens (RE) lesion impacts on the function of prefrontal cortex (PFC)-hippocampus circuitry. (a) Schematic representation of PFC-RE-hippocampus circuitry. (b) An atlas reference diagram from Paxinos and Watson¹⁷ and a slice photomicrograph of the RE lesion. (c, d) Overall CA1 and PFC activity as measured by power spectrum densities was comparable in the sham and lesion groups. (e) PFC-hippocampus coherence was decreased in lesioned rats, in comparison to sham controls. + denotes a significant lesion effect, P < 0.05.

excluded from the analysis,^{16,19} and animals with a lesion covering $\geq 10\%$ of any other brain area in the vicinity of the RE were likewise excluded. Rats with sparing of the RE were excluded from the analysis (35% for the electrophysiology experiment, 11% for the FST experiments and 8% for the CMS experiments).^{14,16,19}

Experiment 1: Electrophysiological studies in RE-lesioned rats

2

Animals (n = 4 per group) were anesthetized (sodium pentobarbital 60 mg kg⁻¹, i.p., supplemented every 60 min throughout the experiment) and placed in a stereotaxic frame (David Kopf Instruments); rectal temperature was maintained at 37 °C by a homoeothermic blanket (Stoelting, Dublin, Ireland). To assess RE-modulated activation and synchrony within the PFC and hippocampus pathway, platinum/iridium recording electrodes (Science Products, Hofheim, Germany) were placed in the prelimbic frontal cortex and a concentric bipolar tungsten/ stainless-steel electrode (World Precision Instruments, Sarasota, FL, USA) was positioned into the ipsilateral CA1/subicular region of the ventral hippocampus (-3.3 mm AP, ±0.8 mm ML, and -4.0 mm DV from skull for the PL; +6.5 mm AP, ±5.5 mm ML, and -5.3 mm DV from skull for the hippocampus), as described previously.^{2,5,22} Recorded extracellular local field potentials were amplified, filtered (0.1-300 Hz, LP511 Grass Amplifier, Astro-Med, Rodgau, Germany), acquired (Micro 1401 mkll, Cambridge Electronic Design, Cambridge, UK) and recorded at a sampling rate of 1000 Hz on a personal computer running the Signal Software (CED). After the electrophysiological protocols, a biphasic 1 mA stimulus was delivered to both electrodes. Thereafter, rats were killed and perfused with 4% paraformaldehyde (PFA) to verify correct placement of the recording electrodes; data from animals in which electrodes were misplaced were discarded.

Experiment 2: FST in the presence of RE lesion or RE inactivation *Forced swim test.* The FST, a standard test for screening the antidepressant potential of various interventions, was carried out as previously described.^{23–27} Briefly, 1 week after surgical lesions or transient pharmacological inactivation of the RE, rats were placed in a cylindrical tank $(60 \times 19 \text{ cm}^2, \text{ filled to a height of 40 cm with water at a temperature of <math>24 \pm 1 \text{ °C}$) and were forced to swim for 15 min during a pretest (training) session. After 24 h, animals were subjected to a 5 min swimming session (test session).²⁸ Behavior was scored using Kinoscope open-

source software (https://sourceforge.net/projects/kinoscope). Sertraline was added in this experiment, as a positive control, and sham-operated animals were given an i.p. injection of the antidepressant sertraline (10 mg kg⁻¹) or vehicle 23, 5 and 1 h before the FST test session (n = 8-12 per group).^{29,30}

RE inactivation. To investigate whether temporary RE inactivation would have the same effects in the FST as permanent RE lesions, a different set of rats was used for RE inactivation studies during FST (*n* = 8 per group). For RE inactivation, injection needles were introduced via a stainless steel guide cannula (0.4 mm in diameter) implanted in the RE (1.0 mm above the targeted site to allow the tip of the infusion needle to protrude into the tissue).²¹ Five minutes before the FST pretest or test session, 0.6 µl of tetracaine (Sigma, St Louis, MO, USA; 2% w/v dissolved in PBS)¹⁴ was slowly infused (3.5 min; 0.2 µl min⁻¹) to prevent tissue damage using a micropump (CMA-100; CMA/Microdialysis, Kista, Sweden).^{14,19} To facilitate postmortem evaluation of RE inactivation, 1% w/v cresyl violet was added in the tetracaine solution.^{14,16,19}

Open field test. This test was used to assess the impact of surgical RE lesions on locomotor activity. For this, an open field (OF) apparatus (square arena 43.2×43.2 cm²) surrounded by tall Perspex walls (Med Associates, St Albans City, VT, USA) was used. Sham-operated and RE-lesioned animals were placed in the center and allowed to explore the area for 10 min. Infrared beams and the manufacturer's software were used to automatically register exploration of the arena.²³

c-FOS immunostaining. To investigate whether the RE is activated following swim stress, c-FOS immunostaining³¹ was performed on brain sections from sham-operated rats exposed to the FST. Briefly, 90 min after the last FST session, animals (n = 5 per group) were anesthetized and perfused with 4% PFA (in 0.1 M PBS) before careful excision of the brain, postfixation (4% PFA) and transfer to 30% sucrose (in PBS 0.1 M). After incubation in 0.3% Triton X-100/0.1 M glycine/10% fetal bovine serum, 50 µm sections were cut on a vibratome and incubated with c-FOS antibody (1:10 000; overnight, cat. no. PC05, Calbiochem, Darmstadt, Germany). Sections were then incubated in biotinylated goat anti-rabbit antibody (cat. no. E0432, Dako, Glostrup, Denmark) and Avidin/Biotin Complex (ABC solution; Vectorstain Elite, Burlingame, CA, USA). Neurons in the RE that were c-FOS-immunoreactive were counted using the StereoInvestigator software (MicroBrightField). Immunoreactive c-FOS



Figure 2. Nucleus reuniens (RE) lesion exhibits antidepressant effect in forced swim test (FST). (**a**) Lesion of RE before FST procedure and alternatively a temporary RE inactivation either at the 'pretest' or 'test' swim session, prevented the appearance of depressive-like behavior by reducing immobility duration in the second, 'test' swim session, similar to sertraline administration. (**b**) All RE activity manipulations lengthened the active, swimming behavior, as sertraline did. (**c**) FST increased c-FOS-expressing neuron density in RE. *Denotes a significant stress effect, #a significant treatment effect and +a significant lesion effect, P < 0.05.

was visualized with diaminobenzidine before light counterstaining with hematoxylin. For double-labeling experiments, c-FOS was detected by immunofluorescence. For this, antigen retrieval was achieved using the citrate buffer before overnight incubation (4 °C) of 50 µm sections (vibratome-cut) with antisera against c-FOS (1:500; cat. no. AB1584, Millipore, Darmstadt, Germany) and calretinin (1:500; cat. No. AF5065, R&D Systems, Minneapolis, MN, USA) and counterstaining with 4',6-diamidino-2-phenylindole (1 µg ml⁻¹). Labeled cells in the RE were counted using an Olympus BX51 microscope (Olympus, Tokyo, Japan).

Experiment 3: Effects of CMS in RE-lesioned rats

Chronic mild stress. A slightly modified version of a previously described CMS protocol^{32–35} was used in RE-lesioned rats, in order to investigate the role of the RE in this model of depression (see Supplementary Table 1). Four groups of animals (control/sham-operated, n=15; control/RE-lesioned, n=12; CMS/sham-operated, n=14; and CMS/RE-lesioned, n=13) were used. During the last 3 weeks of CMS, each of these groups was subdivided (n=6-8 per group); half of the rats received daily i.p. injections of the antidepressant sertraline (10 mg kg⁻¹ day⁻¹, as a positive control) while the other half received vehicle (0.9% saline i.p.).

Sucrose preference test. Anhedonia, a core symptom of depression, was monitored using the sucrose preference test (SPT) on a weekly basis after initiation of the CMS protocol.^{33,36} Animals that had been food and water deprived (18 h) were presented with two preweighed bottles, one containing a 1% sucrose solution and the other containing tap water, over a period of 1 h. Sucrose preference was calculated according to the formula: sucrose preference=(sucrose intake/(total fluid intake)) and expressed as a percentage. Following collection of sucrose preference data at week 0 (baseline), animals were assigned to the control and CMS groups, as before.^{32,35} Briefly, rats were assigned to the control and CMS groups alternating from highest to lowest preference, so as the difference of means between the two groups would be the lowest possible.

OF test and FST. Twelve hours after the end of the CMS protocol, all animals were subjected to the OF test to monitor locomotor activity and 24 h later to the FST, as described above (experiment 2).

Tissue collection. Rats were anesthetized (pentobarbital) and PFAperfused immediately after the second (test) session of the FST; just before the perfusion, a blood sample was withdrawn (under anesthesia) from the right ventricle of the heart for the eventual assay of corticosterone using a commercially available kit (ICN Biomedical, Costa Mesa, CA, USA; inte-assay coefficient of variation: 8%).^{25,32,37} Adrenals were carefully dissected and weighed upon killing (Supplementary Figure S4).

Neurostructural analysis. To investigate the role of the PFC–hippocampus circuit in CMS-induced neuromorphological changes, rats exposed to CMS and their corresponding controls were perfused with saline; brains were collected and immersed in Golgi–Cox solution for 14 days before transfer to a 30% sucrose solution. Coronal vibratome sections (200 µm) were collected in 6% sucrose, dried onto gelatin-coated microscope slides, alkalinized in 18.7% ammonia, developed in Dektol (Kodak, Linda-a-Velha, Portugal), fixed, dehydrated and mounted, as previously described.^{33,38,39} Dendritic arborization, spine density and spine shape of neurons in the RE

and layer II/III of the prelimbic area of the mPFC (n = 5 for all groups; 6 neurons per each animal) were subsequently analyzed. Briefly, for each selected neuron, all branches of the dendritic tree were reconstructed using a motorized microscope (Axioplan 2; Carl Zeiss, Oberkochen, Germany) and the Neurolucida software (MicroBrightField) and the dendritic length was automatically calculated. Dendritic spine density (number of spines/dendritic length) was determined in the proximal (60–120 µm) and distal (140–200 µm) parts of the apical dendritic tree. To assess changes in spine morphology, spines in the selected segments were classified into mushroom-shaped, thin, wide and ramified spines, according to Harris;⁴⁰ the proportion of spines in each category was calculated for each neuron. A Sholl analysis (index of dendritic complexity and degree of arborization) was also conducted; the number of dendritic intersections with concentric spheres positioned at radial intervals of 20 µm from the soma was assessed using NeuroExplorer software (MicroBrightField), as previously described.33

Experiment 4: Effects of RE lesioning before vs during exposure to CMS

Chronic mild stress. The next CMS experiment followed the same protocol as described above in experiment 3. The purpose of this experiment was to investigate whether RE lesions can prevent or reverse CMS-induced changes. A new set of animals were given a sham operation or an RE lesion, and 1 week later, they were subjected to CMS. Four weeks into the CMS, the protocol was suspended and previously sham-operated animals were given a second sham operation or received an RE lesion. Rats were allowed 3 days to recover from surgery and CMS resumed with the resulting three experimental groups: 6 rats with RE lesion before CMS, 7 rats with RE lesion during CMS, and 9 sham-operated rats. The CMS protocol continued for further 6 weeks and SPTs were performed as described above.

Dexamethasone suppression test. At the end of the CMS, a dexamethasone suppression test (DST) was administered to all animals, in order to assess the glucocorticoid-negative feedback sensitivity of the hypothalamus–pituitary–adrenal (HPA) axis.⁴¹ Briefly, all animals received an injection of either dexamethasone (100 µg kg⁻¹, i.p.) or vehicle (0.9% saline) before being subjected to a swim stress (at 24 ± 1 °C) for 15 min. Two hours later, rats were killed and blood samples were analyzed for corticosterone levels, as described above. Data are presented as the relative percentage of changes of corticosterone levels in the corresponding group pairs (dexamethasone-injected vs saline-injected).⁴¹

Statistical analysis

Sample sizes were determined by power analysis, based on effects sizes previously observed in previous similar experiments performed by the authors, at 80% power and type I error equal to 5%. After testing for normality and homogeneity, appropriate statistical tests were applied to the data. Repeated-measures analysis of variance was used to analyze results from the SPT. One-way, two-way and three-way analysis of variance were used, as appropriate, to evaluate other behavioral data as well as morphological, electrophysiological, hormonal and immunohistochemical results. Differences between groups were then determined by Bonferonni's *post hoc* analysis. Significance level was set at P=0.05. All results are expressed as mean ± s.e.m.

Role of the nucleus reuniens V Kafetzopoulos *et al*



Figure 3. Nucleus reuniens (RE) is essential for depressive behavior and neuronal deficits induced by chronic stress. (**a**) RE lesion prevented chronic mild stress (CMS)-induced decreased sucrose preference. Sertraline treatment at week 4 reversed CMS-induced decreased sucrose preference. (**b**) CMS significantly increased immobility duration. Sertraline reduced immobility only in sham-operated animals and RE lesion resulted in decreased immobility only in vehicle-treated rats. (**c**) In contrast, RE lesion and sertraline increased swimming in control and CMS rats. *Denotes a significant stress effect, #a significant treatment effect and +a significant lesion effect, P < 0.05.

RESULTS

4

RE lesion impacts on the function of PFC-hippocampus circuitry and elicits antidepressant-like effects

Network dynamics in the PFC-hippocampus loop were compared between sham-operated and RE-lesioned rats by simultaneously recording neuronal activity in the medial PFC and ventral hippocampus. Power spectrum densities and coherence analyses, based on local field potentials, were used as indicators of power activity and phase coherence between the PFC and hippocampus.^{5,42} As shown on Figure 1, RE lesioning did not alter overall activity in the hippocampus (Figure 1c) and PFC (Figure 1d), evidenced by monitoring power spectrum densities at several frequency bands. However, coherence between firing in the PFC and hippocampus was significantly reduced in RE-lesioned animals; specifically, as compared with their shamoperated controls, RE-lesioned animals displayed reduced theta and beta frequency bands; the same tendency was observed for gamma frequency bands (Figure 1e; lesion main effect: theta: $F_{1,6} = 82.46$, P < 0.001; beta: $F_{1,6} = 20.74$, P = 0.004 and gamma: $F_{1,6} = 5.59, P = 0.056$).

Using the FST, which is used widely to assess the antidepressant potential of drugs and various interventions,⁴³ we found that RE-lesioned animals exhibited lower immobility levels than shamoperated animals during the second FST session (Figure 2a). Interestingly, the duration of immobility observed in RE-lesioned animals was comparable to that observed in rats that received sertraline, an antidepressant drug employed in this study as positive control. Similar antidepressant effects were apparent when the RE was transiently inactivated with tetracaine either before the 'pretest' (first) or 'test' (second) FST session (Figure 2a) (inactivation main effect: $F_{3,32} = 49.50$, P < 0.001; post hoc: lesion vs sham P < 0.001, 'pretest' inactivation vs sham P < 0.001, 'test' inactivation vs sham P < 0.001; main effect of sertraline treatment: $F_{1.18} = 50.68$, P < 0.001). Rats with transient inactivation (tetracaine-induced) or permanent excitotoxic lesion (N-methyl-Daspartate-induced) of the RE showed duration of swimming behavior that was greater than that observed in sham-operated rats. Moreover, swimming duration was comparable in RE-lesioned and sertraline-treated animals (Figure 2b) (inactivation main effect: F_{3,32} = 27.63, P < 0.001, post hoc: lesion vs sham P < 0.001, 'pretest' RE inactivation vs sham P < 0.001, 'test' RE inactivation vs sham P = 0.002; treatment main effect F_{1,18} = 51.29, P < 0.001). Climbing duration did not differ significantly between any of the groups (data not shown).

Complementing the above results, we observed in shamoperated rats that FST activates the RE because there was an increase in the density of c-FOS immunoreactive cells (Figure 2c; FST main effect: $F_{1,8} = 240.6$, P < 0.001). Interestingly, after the FST the percentage of calretinin cells that co-expressed c-FOS did not change significantly (Supplementary Figure S2; FST main effect: $F_{1,6} = 2.465$, P = ns).

Finally, RE lesion did not affect neither the locomotor activity, measured by ambulation in an OF arena, nor the amount of time spent in the center of the arena (lesion main effect: $F_{1,19} = 0.20$, P = NS and $F_{1,19} = 0.04$, P = NS, respectively; Supplementary Figures 3a and b). These behavioral findings concur with previously published observations.¹⁹

Role of RE in eliciting depressive-like behavior supported by behavioral and neuromorphological measures

CMS is an acknowledged paradigm for inducing depressive-like behavior in rodents.³⁵ Anhedonia, which is a core symptom of depression, can be modeled in rodents using the SPT, and in agreement with numerous previous studies,^{23,32} the CMS paradigm successfully decreased sucrose preference after 4 weeks. Moreover, treatment with sertraline in the following 3 weeks reversed the CMS-induced anhedonia (Figure 3a). Importantly, lesions of the RE prior to exposure to the 7-week CMS paradigm abrogated the CMS-induced anhedonia (time × CMS × lesion interaction: $F_{5,250} = 2.46$, P = 0.034, CMS × treatment interaction $F_{1,47} = 4.97$, P = 0.031, *post hoc*: sertraline–CMS vs vehicle–CMS P = 0.025; Figure 3a).

The duration of immobility in the FST was enhanced by CMS and decreased by sertraline in both control and CMS-exposed rats (Figure 3b). Importantly, all RE-lesioned rats (control and CMSexposed) exhibited reduced immobility in the FST (CMS×treatment × lesion interaction: F_{1,46} = 6.657, P = 0.013, post hoc: lesionvehicle-CMS vs sham-vehicle-CMS P < 0.001, lesion-vehiclecontrol vs sham-vehicle-control P < 0.001, sertraline-sham-CMS vs vehicle-sham-CMS P < 0.001, sertraline-sham-control vs vehicle-sham-control P < 0.001, CMS-vehicle-sham vs controlvehicle-sham P = 0.001). In addition, sertraline treatment and RE lesioning increased the time spent swimming in control and CMS rats (Figure 3c; treatment × lesion interaction: $F_{1.46} = 19.83$, P < 0.001, post hoc: lesion-vehicle vs sham-vehicle P < 0.001, sertraline-sham vs vehicle-sham P < 0.001). Finally, sertraline and RE lesioning reduced serum corticosterone levels (treatment and lesion main effect: $F_{1,46} = 4.64$, P = 0.037 and $F_{1,46} = 4.09$, P = 0.049; Supplementary Figure S4). Taken together, all findings show that disruption of RE function prevents the establishment of depressive-like behavior in CMS.

Consistent with the absence of CMS-induced depressive-like behavior in RE-lesioned rats, these animals did not display neurostructural changes in the PFC after CMS. Specifically, RE lesioning prevented the atrophy of dendrites of PFC neurons that follows exposure to CMS³³ (Figures 4a and b; lesion×CMS interaction: $F_{1,32}$ =7.14, P=0.012, post hoc: lesion–CMS vs sham–CMS P=0.002, CMS–sham vs control–sham P=0.002, n=5 per group). Similar to RE lesioning, sertraline also counteracted

Role of the nucleus reuniens V Kafetzopoulos *et al*



Figure 4. Chronic mild stress (CMS)-evoked dendritic deficits of prefrontal cortex (PFC) neurons, which were attenuated by nucleus reuniens (RE) lesion. (**a**) RE lesion prevented and sertraline reversed CMS-induced reduction of dendritic length of PFC neurons. (**b**) Depiction of threedimensional reconstructed cortical pyramidal neurons. Scale bar: 50 μ m. (**c**) RE lesion also prevented the CMS-induced spine density decrease at the apical dendrites of PFC neurons. (**d**) Representative photomicrographs of spine-bearing branches. The "t" indicates a thin spine and the "m" a mushroom spine. Scale bar: 5 μ m; *denotes a significant stress effect, #a significant treatment effect and +a significant lesion effect, P < 0.05.

CMS-induced dendritic atrophy in PFC neurons (Figures 4a and b; treatment × CMS interaction $F_{1,32} = 5.47$, P = 0.026, post hoc: sertraline–CMS vs vehicle–CMS P = 0.002, n = 5 per group). Sertraline itself did not affect dendritic length of RE neurons (treatment main effect: $F_{1,16} = 0.69$, P = NS, n = 5 per group), whereas there was a tendency for CMS to increase dendritic length in RE neurons (CMS main effect $F_{1,16} = 3.94$, P = 0.065) (Supplementary Figure S5).

Protection against CMS-induced reductions in PFC apical dendrite spine density was another important effect that resulted from either RE lesioning or sertraline treatment (lesion × CMS interaction: F_{1.32}=4.82, P=0.035, post hoc: lesion-CMS vs sham-CMS P = 0.006, sham–CMS vs sham–control P < 0.001, treatment × CMS interaction: $F_{1,32} = 5.36$, P = 0.027, post hoc: sertraline–CMS vs vehicle–CMS P = 0.001, n = 5 per group; Figures 4c and d). As shown in Figure 5, in sham-operated animals CMS slightly reduced, whereas sertraline significantly increased the percentage of mushroom spines in the proximal part of apical dendrites in the PFC (CMS main effect $F_{1.16} = 4.38$, P = 0.053; treatment main effect $F_{1.16} = 4.72$, P = 0.045; Figure 5a). These effects were not evident in RE-lesioned animals (CMS main effect $F_{1,16} = 0.56$, P = NS; treatment main effect $F_{1,16} = 3.04$, P = NS; Figure 5a). Importantly, whereas CMS decreased the relative number of mushroom spines, RE lesions prevented this effect (post hoc: sham-CMS vs shamcontrol P = 0.031; lesion–CMS vs lesion–control P = NS). Sertraline increased the percentage of mushroom spines at the distal segments of apical dendrites in all, but the CMS RE-lesioned animals (post hoc control: sham-sertraline vs sham-vehicle P = 0.004; lesion-sertraline vs lesion-vehicle P = 0.024; CMS: sham-sertraline vs sham-vehicle P = 0.037), (Figure 5b).

In the proximal portion of the apical dendrite in PFC pyramidal neurons, CMS elevated thin spine percentage (CMS main effect $F_{1,32} = 4.45$, P = 0.043) (Figure 5c). In the distal part, sertraline

treatment reduced and CMS increased thin spine percentage in sham-operated rats (treatment and CMS main effects: $F_{1,16}$ = 8.41, P = 0.01 and $F_{1,16}$ = 19.91, P < 0.001, respectively) while in lesioned rats sertraline reduced thin spine percentage only in controls (CMS × treatment interaction: $F_{1,16}$ = 5.56, P = 0.031; *post-hoc*: sertraline-control vs vehicle-control P = 0.023), (Figure 5d). Results from Sholl analyses showed that dendritic arborization of the apical dendrites of PFC neurons was similarly increased by both RE lesioning and sertraline treatment in comparison to shamoperated and vehicle-treated rats, respectively (Figure 5e; $F_{2.47,78.90}$ = 3.36, P = 0.031 and $F_{2.47,78.90}$ = 3.00, P = 0.045, lesion and treatment main effect, respectively). Thus, similar to sertraline treatment, RE lesions spare PFC neurons from CMS-induced reductions in the dendritic complexity of PFC neurons.

RE lesions prevent, but do not mitigate, CMS effects

Having demonstrated that the manifestation of depressive-like behavior after CMS depends on an intact RE, we next asked whether the CMS-induced depressive-like behavior and HPA axis dysregulation could be reversed or ameliorated by introducing RE lesions not before but during CMS. In this second CMS experiment, we successfully repeated our previous CMS finding, as animals with an RE lesion before CMS exposure did not exhibit anhedonia and had higher sucrose preference compared with sham-operated animals (lesion main effect: F_{1,20}=5.148, P=0.034). Interestingly, animals that received an RE lesion during CMS were not different from sham-operated animals, thus exhibiting anhedonia that did not appear if RE lesion was performed before CMS (lesion main effect: F_{2.19}=4.676, P=0.022, post hoc: sham vs pre-CMS lesion P = 0.032, sham vs during CMS lesion P = 1.0; Supplementary Figure S6a). Moreover, CMS has been shown to elicit HPA axis dysregulation^{44,45} similar to the one often seen in depressed

Role of the nucleus reuniens V Kafetzopoulos *et al*



Figure 5. Impact of nucleus reuniens (RE) lesion on spine morphology and dendritic arborization. (**a**) Chronic mild stress (CMS) marginally reduced and sertraline clearly increased mushroom spine percentage in the proximal part of the apical dendrites in sham- but not in lesion-operated rats. (**b**) In the distal portion, CMS sham-operated but not lesioned rats had decreased mushroom spine percentage. Sertraline increased the mushroom percentage in all cases except CMS lesioned animals. (**c**) In the proximal portion of the apical dendrite in PFC pyramidal neurons, CMS uniformly elevated thin spine percentage. (**d**) In the distal part, sertraline treatment reduced and CMS increased thin spine percentage only in controls. (**e**) RE lesion and sertraline increased dendritic arborization. *Denotes a stress effect, #a treatment effect and +a lesion effect. PFC, prefrontal cortex.

patients.⁴⁶ Therefore, we employed the DST to monitor the expected disruption of the negative feedback of the HPA axis while under CMS.⁴⁷ In accordance with the behavioral resilience to CMS, animals with an RE lesion before CMS displayed a suppressed corticosterone response following dexamethasone despite CMS. Instead, sham-operated rats and rats that received an RE lesion during CMS displayed the depressive-like non-suppression in the DST (DST main effect: $F_{2,6} = 23.529$, P = 0.001, *post hoc*: lesion before CMS vs sham: P = 0.003, lesion before CMS vs lesion during CMS: P = 0.003; Supplementary Figure S6b). Taken together, findings from this experiment suggest that the RE is essentially involved in the establishment phase of depressive symptomatology rather than in processes recruited for recovering from depression.

DISCUSSION

6

The present experimental study provides novel evidence for the intermediary, but pivotal, role of the RE in synchronizing communication between the PFC and hippocampus. In this regard, the data presented here support and extend previous suggestions that the

RE thalamic nucleus forms an integral part of the PFC–hippocampal circuitry.^{8,9} Specifically, we show that the RE is essential for maintaining phase coherence between the PFC and the hippocampus. We also report that the RE has a crucial role in the manifestation of a depressive-like state and related behavioral, neuromorphological and endocrine effects. Although previous authors suggested RE involvement in the processing of emotional and cognitive information,^{11,48} our observations are important because they pinpoint a neuroanatomical network that may be targeted to increase resilience against mood disorders, such as major depression.

The suggestion that the RE is implicated in the PFC/ hippocampus-dependent behavioral response is supported by our finding that the FST paradigm, which enhances corticosterone levels,^{25,49} leads to a significant RE activation. This is in line with a previous finding that a short exposure to an acute stressor activates the RE⁵⁰ and suggests a role of the RE in the stress response. Also relevant is to notice that an earlier report showed that antidepressant-like effects are elicited by lesions of the ventral PFC;⁵¹ in our study, we triggered an antidepressant response, namely, reduced immobility and increased swimming duration in the FST and abrogation of anhedonia in the CMS,⁵² not by lesioning the PFC but instead by lesioning a thalamic nucleus at the interplay between PFC and hippocampus.

Notably, the RE lesion and antidepressant treatment triggered behavioral responses of comparable effect size. However, it is important to note that RE inactivation at any of the two FST sessions (pretest and test) resulted in the same antidepressant-like behavioral response. Interestingly, the anhedonia during CMS, the depressive-like behavior in the FST after CMS and the disruption of the HPA axis could only be prevented when the RE lesions preceded CMS. In contrast, lesions of the RE midway through the CMS protocol failed to reverse the behavioral and endocrine anomalies induced by CMS. These observations point not only to the critical role of the RE in the stress response and its detrimental effects but may also relate to differences between the two models (FST, CMS).⁵² Although CMS is known for its face and construct validity, more closely modeling the human condition, the FST excels for its predictive validity of potential antidepressant manipulations, either before or in between the two FST sessions.

Importantly, along with the behavioral resilience, RE lesions also prevented in the PFC the appearance of CMS-induced deficits in neuroplasticity (for example, dendritic atrophy and spine loss), which have been associated with depressive-like behavior.^{33,53} It should be noted here that the RE predominantly projects to superficial layers of the PFC,⁵⁴ which are the most affected by CMS.^{53,55–57} It is thus suggested that, in rats with an intact RE, the depressive-like morphological (plasticity) changes observed after CMS in PFC neurons may be a result of the CMS-induced change on the PFC-hippocampus crosstalk. Importantly, antidepressant (sertraline) treatment and RE lesion resulted in a similar morphological alteration of plasticity indices, such as spine density and dendritic arborization. This suggests that a PFChippocampus decoupling and an antidepressant treatment may partially share a common underlying mechanism of action, however, with a significant difference: PFC-hippocampus decoupling may prevent the establishment of depressive-like symptoms, whereas antidepressant pharmacotherapy may prevent and restore depressive-like symptoms in animal models of depression. Moreover, our findings on the DST are consistent with the experimental and clinical data, which demonstrate that often an altered HPA axis negative feedback associates with the appearance of depressive-like symptomatology.⁵⁸ Taken together, these findings show that the prevention of depressive-like behavior by RE lesion extends not only to the behavioral response but also to neuroendocrine and brain neuroplasticity findings that are highly related to the pathophysiology of depression.

In light of the recently emerging view that chronic stress shifts the overall brain connectome, it is relevant to examine the involvement of RE on the suggested switch between circuitries along the transition from acute stress condition to chronic stress brain construct. For this purpose, it is relevant to explore the contribution of different RE neuronal populations to this effect. Previously, it was demonstrated that calretinin-stained neurons project in the hippocampal CA1 region.⁵⁹ In this study, calretinin staining showed a high degree of co-localization with c-FOSactivated cells, thus highlighting the involvement of RE glutamate interneurons at the PFC-hippocampus communication. Lesioning of these interneurons produced the resilience to depression presented here. However, a limitation of this study is that, in contrast to humans, rodents may be virtually devoid of GABA interneurons in the RE relay nucleus.^{59,60} Thus it is not yet clear whether disrupting both GABA and glutamate RE interneurons or specifically the later subpopulation would replicate our findings in humans. Finally, given the observed RE activation during FST in sham-operated animals, an optogenetic-based approach for activating RE during FST and/or CMS would also provide additional insight.

7

In conclusion, the present work pinpoints the RE as an important relay station in PFC-hippocampus communication and demonstrates that the refinement of cortical information flow by this specific thalamic nucleus is critical for mood regulation as well as the establishment of depressive-like pathology.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGMENTS

We thank the excellent technical assistance provided by Mrs D Papassava and Mrs Goreti Pinto. We also thank Dr R Matsas and Dr M Thomaidou (Athens Pasteur Institute), Dr S Pagakis (BRFAA) for providing equipment and Specifar S.A., Greece for providing sertraline. This work was supported by an 'Education and Lifelong Learning, Supporting Postdoctoral Researchers', co-financed by the European Social Fund (ESF) and the General Secretariat for Research and Technology, Greece, the Life and Health Sciences Research Institute (ICVS), ON.2—O NOVO NORTE—North Portugal Regional Operational Program 2007/2013 of the National Strategic Reference Framework (NSRF) 2007/2013 through the European Regional Development Fund (ERDF), the Portuguese Foundation for Science and Technology (FCT; grant no. NMC-113934) and an InEurope program funded by International Brain Research Organization. NK was funded for the FST behavioral scoring software by an IKY-Siemens Fellowship of Excellence for Postgraduate Studies. VMS and JFO were funded by FCT and Marie Curie IEF fellowships as well as the Bial Foundation.

AUTHOR CONTRIBUTIONS

VK contributed to the design of the study, performed all experimental procedures, statistical analyses and compiled the first draft. NK contributed to the design of the study, the analysis and interpretation of results and, with AV, participated in some of the experiments; JFO and VMS helped with the electrophysiological analyses. IS and HL-A contributed to the histochemical analyses. IS and OFXA helped with the studies involving stress and data interpretation. ZP-D, KA and NS participated in study design and interpretation of results and provided significant insights. CD supervised and contributed to all parts of this project. All authors contributed to the writing of the manuscript and approved the final manuscript.

REFERENCES

- 1 Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. *Science* 2012; **338**: 68–72.
- 2 Cerqueira JJ, Mailliet F, Almeida OF, Jay TM, Sousa N. The prefrontal cortex as a key target of the maladaptive response to stress. J Neurosci 2007; 27: 2781–2787.
- 3 Price JL, Drevets WC. Neural circuits underlying the pathophysiology of mood disorders. *Trends Cogn Sci* 2012; **16**: 61–71.
- 4 Spinelli S, Muller T, Friedel M, Sigrist H, Lesch KP, Henkelman M et al. Effects of repeated adolescent stress and serotonin transporter gene partial knockout in mice on behaviors and brain structures relevant to major depression. Front Behav Neurosci 2013; 7: 215.
- 5 Oliveira JF, Dias NS, Correia M, Gama-Pereira F, Sardinha VM, Lima A et al. Chronic stress disrupts neural coherence between cortico-limbic structures. Front Neural Circuits 2013; 7: 10.
- 6 Siapas AG, Lubenov EV, Wilson MA. Prefrontal phase locking to hippocampal theta oscillations. *Neuron* 2005; **46**: 141–151.
- 7 Vertes RP. Analysis of projections from the medial prefrontal cortex to the thalamus in the rat, with emphasis on nucleus reuniens. *J Comp Neurol* 2002; **442**: 163–187.
- 8 Xu W, Sudhof TC. A neural circuit for memory specificity and generalization. *Science* 2013; **339**: 1290–1295.
- 9 Di Prisco GV, Vertes RP. Excitatory actions of the ventral midline thalamus (rhomboid/reuniens) on the medial prefrontal cortex in the rat. *Synapse* 2006; **60**: 45–55.
- 10 Zhang Y, Yoshida T, Katz DB, Lisman JE. NMDAR antagonist action in thalamus imposes delta oscillations on the hippocampus. J Neurophysiol 2012; 107: 3181–3189.
- 11 Zimmerman EC, Grace AA. The nucleus reuniens of the midline thalamus gates prefrontal-hippocampal modulation of ventral tegmental area dopamine neuron activity. J Neurosci 2016; 36: 8977–8984.
- 12 Layfield DM, Patel M, Hallock H, Griffin AL. Inactivation of the nucleus reuniens/ rhomboid causes a delay-dependent impairment of spatial working memory. *Neurobiol Learn Mem* 2015; **125**: 163–167.

- 13 Hallock HL, Wang A, Griffin AL. Ventral midline thalamus is critical for hippocampalprefrontal synchrony and spatial working memory. J Neurosci 2016; 36: 8372–8389.
- 14 Davoodi FG, Motamedi F, Akbari E, Ghanbarian E, Jila B. Effect of reversible inactivation of reuniens nucleus on memory processing in passive avoidance task. *Behav Brain Res* 2011; **221**: 1–6.
- 15 Polissidis A, Chouliara O, Galanopoulos A, Rentesi G, Dosi M, Hyphantis T et al. Individual differences in the effects of cannabinoids on motor activity, dopaminergic activity and DARPP-32 phosphorylation in distinct regions of the brain. Int J Neuropsychopharmacol 2009; 13: 1175–1191.
- 16 Hembrook JR, Mair RG. Lesions of reuniens and rhomboid thalamic nuclei impair radial maze win-shift performance. *Hippocampus* 2011; 21: 815–826.
- 17 Paxinos G, Watson C. *The Rat Brain in Stereotaxic Coordinates*5th edn. Elsevier Academic Press: Amsterdam, The Netherlaands; Boston, MA, USA, 2005.
- 18 Dolleman-van der Weel MJ, Morris RG, Witter MP. Neurotoxic lesions of the thalamic reuniens or mediodorsal nucleus in rats affect non-mnemonic aspects of watermaze learning. Brain Struct Funct 2009; 213: 329–342.
- 19 Loureiro M, Cholvin T, Lopez J, Merienne N, Latreche A, Cosquer B *et al.* The ventral midline thalamus (reuniens and rhomboid nuclei) contributes to the persistence of spatial memory in rats. *J Neurosci* 2012; **32**: 9947–9959.
- 20 Prasad JA, Macgregor EM, Chudasama Y. Lesions of the thalamic reuniens cause impulsive but not compulsive responses. *Brain Struct Funct* 2013; **218**: 85–96.
- 21 Cholvin T, Loureiro M, Cassel R, Cosquer B, Geiger K, De Sa Nogueira D *et al.* The ventral midline thalamus contributes to strategy shifting in a memory task requiring both prefrontal cortical and hippocampal functions. *J Neurosci* 2013; **33**: 8772–8783.
- 22 Rocher C, Spedding M, Munoz C, Jay TM. Acute stress-induced changes in hippocampal/prefrontal circuits in rats: effects of antidepressants. *Cereb Cortex* 2004; **14**: 224–229.
- 23 Dalla C, Antoniou K, Kokras N, Drossopoulou G, Papathanasiou G, Bekris S et al. Sex differences in the effects of two stress paradigms on dopaminergic neurotransmission. *Physiol Behav* 2008; **93**: 595–605.
- 24 Kokras N, Antoniou K, Dalla C, Bekris S, Xagoraris M, Ovestreet DH *et al.* Sex-related differential response to clomipramine treatment in a rat model of depression. *J Psychopharmacol* 2009; **23**: 945–956.
- 25 Kokras N, Dalla C, Sideris AC, Dendi A, Mikail HG, Antoniou K et al. Behavioral sexual dimorphism in models of anxiety and depression due to changes in HPA axis activity. Neuropharmacology 2012; 62: 436–445.
- 26 Drossopoulou G, Antoniou K, Kitraki E, Papathanasiou G, Papalexi E, Dalla C et al. Sex differences in behavioral, neurochemical and neuroendocrine effects induced by the forced swim test in rats. *Neuroscience* 2004; **126**: 849–857.
- 27 Kokras N, Antoniou K, Mikail HG, Kafetzopoulos V, Papadopoulou-Daifoti Z, Dalla C. Forced swim test: what about females? *Neuropharmacology* 2015; **99**: 408–421.
- 28 Cryan JF, Markou A, Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. *Trends Pharmacol Sci* 2002; 23: 238–245.
- 29 Mikail HG, Dalla C, Kokras N, Kafetzopoulos V, Papadopoulou-Daifoti Z. Sertraline behavioral response associates closer and dose-dependently with cortical rather than hippocampal serotonergic activity in the rat forced swim stress. *Physiol Behav* 2012; **107**: 201–206.
- 30 Detke MJ, Rickels M, Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. *Psychopharmacology (Berl)* 1995; **121**: 66–72.
- 31 Ventura-Silva AP, Pego JM, Sousa JC, Marques AR, Rodrigues AJ, Marques F et al. Stress shifts the response of the bed nucleus of the stria terminalis to an anxiogenic mode. Eur J Neurosci 2012; 36: 3396–3406.
- 32 Dalla C, Antoniou K, Drossopoulou G, Xagoraris M, Kokras N, Sfikakis A et al. Chronic mild stress impact: are females more vulnerable? *Neuroscience* 2005; 135: 703–714.
- 33 Bessa JM, Ferreira D, Melo I, Marques F, Cerqueira JJ, Palha JA et al. The moodimproving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling. *Mol Psychiatry* 2009; 14: 764–773, 739.
- 34 Pitychoutis PM, Dalla C, Sideris AC, Tsonis PA, Papadopoulou-Daifoti Z. 5-HT(1A), 5-HT(2A), and 5-HT(2C) receptor mRNA modulation by antidepressant treatment in the chronic mild stress model of depression: sex differences exposed. *Neuroscience* 2012; **210**: 152–167.
- 35 Willner P. Chronic mild stress (CMS) revisited: consistency and behaviouralneurobiological concordance in the effects of CMS. *Neuropsychobiology* 2005; **52**: 90–110.
- 36 Bekris S, Antoniou K, Daskas S, Papadopoulou-Daifoti Z. Behavioural and neurochemical effects induced by chronic mild stress applied to two different rat strains. *Behav Brain Res* 2005; **161**: 45–59.
- 37 Silva R, Mesquita AR, Bessa J, Sousa JC, Sotiropoulos I, Leao P et al. Lithium blocks stress-induced changes in depressive-like behavior and hippocampal cell fate: the role of glycogen-synthase-kinase-3beta. *Neuroscience* 2008; **152**: 656–669.

- 38 Cerqueira JJ, Taipa R, Uylings HB, Almeida OF, Sousa N. Specific configuration of dendritic degeneration in pyramidal neurons of the medial prefrontal cortex induced by differing corticosteroid regimens. *Cereb Cortex* 2007; 17: 1998–2006.
- 39 Dalla C, Whetstone AS, Hodes GE, Shors TJ. Stressful experience has opposite effects on dendritic spines in the hippocampus of cycling versus masculinized females. *Neurosci Lett* 2009; **449**: 52–56.
- 40 Harris KM. Structure, development, and plasticity of dendritic spines. *Curr Opin Neurobiol* 1999; **9**: 343–348.
- 41 Nollet M, Gaillard P, Tanti A, Girault V, Belzung C, Leman S. Neurogenesisindependent antidepressant-like effects on behavior and stress axis response of a dual orexin receptor antagonist in a rodent model of depression. *Neuropsychopharmacology* 2012; **37**: 2210–2221.
- 42 Varela F, Lachaux JP, Rodriguez E, Martinerie J. The brainweb: phase synchronization and large-scale integration. *Nat Rev Neurosci* 2001; **2**: 229–239.
- 43 Cryan JF, Page ME, Lucki I. Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment. *Psychopharmacology (Berl)* 2005; **182**: 335–344.
- 44 Surget A, Tanti A, Leonardo ED, Laugeray A, Rainer Q, Touma C *et al*. Antidepressants recruit new neurons to improve stress response regulation. *Mol Psychiatry* 2011; **16**: 1177–1188.
- 45 Khemissi W, Farooq RK, Le Guisquet AM, Sakly M, Belzung C. Dysregulation of the hypothalamus-pituitary-adrenal axis predicts some aspects of the behavioral response to chronic fluoxetine: association with hippocampal cell proliferation. *Front Behav Neurosci* 2014; **8**: 340.
- 46 Belzung C, Billette de Villemeur E. The design of new antidepressants: can formal models help? A first attempt using a model of the hippocampal control over the HPA-axis based on a review from the literature. *Behav Pharmacol* 2010; 21: 677–689.
- 47 Holsboer-Trachsler E, Stohler R, Hatzinger M. Repeated administration of the combined dexamethasone-human corticotropin releasing hormone stimulation test during treatment of depression. *Psychiatry Res* 1991; **38**: 163–171.
- 48 Vertes RP, Hoover WB, Szigeti-Buck K, Leranth C. Nucleus reuniens of the midline thalamus: link between the medial prefrontal cortex and the hippocampus. *Brain Res Bull* 2007; **71**: 601–609.
- 49 Connor TJ, Kelly JP, Leonard BE. Forced swim test-induced neurochemical endocrine, and immune changes in the rat. *Pharmacol Biochem Behav* 1997; 58: 961–967.
- 50 Cullinan WE, Herman JP, Battaglia DF, Akil H, Watson SJ. Pattern and time course of immediate early gene expression in rat brain following acute stress. *Neuroscience* 1995; 64: 477–505.
- 51 Slattery DA, Neumann ID, Cryan JF. Transient inactivation of the infralimbic cortex induces antidepressant-like effects in the rat. J Psychopharmacol 2011; 25: 1295–1303.
- 52 Kokras N, Dalla C. Sex differences in animal models of psychiatric disorders. Br J Pharmacol 2014; **171**: 4595–4619.
- 53 Dias-Ferreira E, Sousa JC, Melo I, Morgado P, Mesquita AR, Cerqueira JJ *et al.* Chronic stress causes frontostriatal reorganization and affects decision-making. *Science* 2009; **325**: 621–625.
- 54 Vertes RP, Hoover WB, Do Valle AC, Sherman A, Rodriguez JJ. Efferent projections of reuniens and rhomboid nuclei of the thalamus in the rat. *J Comp Neurol* 2006; 499: 768–796.
- 55 Hains AB, Vu MA, Maciejewski PK, van Dyck CH, Gottron M, Arnsten AF. Inhibition of protein kinase C signaling protects prefrontal cortex dendritic spines and cognition from the effects of chronic stress. *Proc Natl Acad Sci USA* 2009; **106**: 17957–17962.
- 56 Liston C, Miller MM, Goldwater DS, Radley JJ, Rocher AB, Hof PR et al. Stress-induced alterations in prefrontal cortical dendritic morphology predict selective impairments in perceptual attentional set-shifting. J Neurosci 2006; 26: 7870–7874.
- 57 Perez-Cruz C, Muller-Keuker JI, Heilbronner U, Fuchs E, Flugge G. Morphology of pyramidal neurons in the rat prefrontal cortex: lateralized dendritic remodeling by chronic stress. *Neural Plast* 2007; 2007: 46276.
- 58 Ising M, Horstmann S, Kloiber S, Lucae S, Binder EB, Kern N et al. Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression - a potential biomarker? *Biol Psychiatry* 2007; 62: 47–54.
- 59 Drexel M, Preidt AP, Kirchmair E, Sperk G. Parvalbumin interneurons and calretinin fibers arising from the thalamic nucleus reuniens degenerate in the subiculum after kainic acid-induced seizures. *Neuroscience* 2011; **189**: 316–329.
- 60 Lara-Vasquez A, Espinosa N, Duran E, Stockle M, Fuentealba P. Midline thalamic neurons are differentially engaged during hippocampus network oscillations. *Sci Rep* 2016; **6**: 29807.

Supplementary Information accompanies the paper on the Molecular Psychiatry website (http://www.nature.com/mp)